Physician profile
Diane E Kerris
NPI 1528103173
$4,099.99
in general payments reported to CMS, 2019-2025
25 companies · $1,014 in 2025
The $1,014 reported for 2025 was more than what 91% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $60.63 · 2020: $139 · 2021: $620 · 2022: $1,034 · 2023: $583 · 2024: $651 · 2025: $1,014.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,247.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,247.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $448.41 | 2021-2025 | Cequa |
| Oyster Point Pharma, INC. | $439.23 | 2022-2025 | Tyrvaya, Ryzumvi |
| Bausch & Lomb Americas INC. | $379.96 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Ani Pharmaceuticals, INC. | $377.79 | 2023-2024 | Purified Cortrophin Gel |
| Alcon Vision LLC | $354.08 | 2019-2025 | Tryptyr, Eysuvis, Precision7 |
| Glaukos Corporation | $349.67 | 2021-2025 | Photrexa Viscous and Photrexa |
| Dompe US, INC. | $224.25 | 2024-2025 | Oxervate |
| Horizon Therapeutics Plc | $198.19 | 2022-2023 | Tepezza |
| Abbvie INC. | $167.21 | 2022-2025 | |
| Tarsus Pharmaceuticals, INC. | $148.76 | 2024-2025 | Xdemvy |
| Kala Pharmaceuticals, INC. | $120.88 | 2021-2022 | |
| Quidel Corporation | $107.59 | 2022 | |
| Genentech USA, INC. | $90.23 | 2020 | |
| Allergan, INC. | $88.46 | 2021-2022 | |
| Sight Sciences, INC. | $86.05 | 2021-2025 | Tearcare System |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $82.88 | 2020-2021 | |
| Aerie Pharmaceuticals, INC. | $82.40 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $75.15 | 2021-2023 | |
| Harrow Eye, LLC | $70.78 | 2024-2025 | Vevye |
| Thea Pharma INC. | $52.24 | 2022 | |
| Amgen INC. | $46.68 | 2025 | Tepezza |
| Abb Con-Cise Optical Group LLC | $44.41 | 2019 | |
| Mallinckrodt Hospital Products INC. | $26.70 | 2025 | Acthar |
| Lkc Technologies, INC. | $20.69 | 2024 | |
| Akorn Operating Company LLC | $17.30 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diane Kerris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.